RT @EBRheum: #ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores.…
Tweet Content
#ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa
Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores.
Good safety profile but too small a trial to assess properly
Overall an encouraging result, JAKi impacting yet another disease!
@RheumNow https://t.co/GtB9wHuoNp
Show on Archive Page
On
Display in Search Results
On